# Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

> **NCT06936215** · PHASE3 · RECRUITING · sponsor: **Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh** · enrollment: 24 (estimated)

## Conditions studied

- Diffuse Cutaneous Systemic Sclerosis

## Interventions

- **DRUG:** tab baricitinib 4 mg daily
- **DRUG:** tab methotrexate 25 mg weekly with folic acid 5 mg weekly

## Key facts

- **NCT ID:** NCT06936215
- **Lead sponsor:** Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06936215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06936215, "Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06936215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*